Correlation between the levels of TSP-1 and VEGF in aqueous humor of patients with neovascular glaucoma

doi:10.3877/cma.j.issn.2095-2007.2018.04.004

Abstract

Abstract:

Objective

To detect new vascular glaucoma(NVG) platelet response eggs in aqueous humor of patients with age-related cataract White-1 (TSP-1) Expression of the situation, and analysis of NVG patients in the aqueous humor TSP-1 and the relationship between vascular endothelial growth factor (VEGF).

Methods

30 NVG patients (NVG group) and 30 age-associated cataract patients (control group) were included. All NVG patients were treated with atrial water before anti-glaucoma surgery and aged cataract surgery. Using enzyme-linked immunosorbent assay to detect aqueous humor and TSP-1 and the VEGF concentration in the blood. Fluid and blood VEGF concentration and the concentration of TSP-1 using the mean±the standard deviation(±s) the independent sample t test was used for inter-group comparison. Spearman's correlation analysis was used to analyze the correlation between various cytokines, cytokine concentration, age and intraocular pressure.

Results

NVG group patients TSP-1 concentration in aqueous humor(15.47±2.28)ng/ml the TSP-1 concentration in aqueous humor as the control group patients(2.28±1.59)ng/ml, NVG group of patients in the aqueous humor TSP-1 concentration significantly higher than the control group, the difference was statistically significant(t=12.70, P<0.05). The VEGF concentrations in aqueous humor of NVG group and control group were, respectively (3355.81±2284.54)pg/ml and(262.68±125.66)pg/ml, The difference was statistically significant(t=7.41, P<0.05). NVG TSP-1 concentration in plasma for patients with group(0.65 ±0.27)ng/ml, the control group patients for TSP -1 in plasma concentration (0.57 ±0.25)ng/ml, concentration between the two groups, there was no statistically significant difference(t=1.16, P>0.05). Plasma concentrations of VEGF were pg/ml in the NVG group and pg/ml in the control group (14.62 ± 6.96). The two comparison, there was no statistically significant difference(t=0.86, P>0.05). NVG patients TSP-1 and VEGF concentration in aqueous humor was significantly positively related to(r=0.479, P<0.05). In the NVG group, there was no significant correlation between the concentration of rh and the plasma concentration, no matter TSP-1 factor or VEGF. Similarly, in the control group, the concentration of atrial water TSP-1 was not correlated with plasma TSP-1, and the concentration of atrial water VEGF was not correlated with plasma VEGF.

Conclusion

The expression of TSP-1 and VEGF was significantly up-regulated in NVG patients, while the expression of TSP-1 was significantly positively correlated with VEGF.

Key words: Neovascular glaucoma, Thrombospondin-1, Vascular endothelial growth factor

Guoli Liu, Ningli Wang. Correlation between the levels of TSP-1 and VEGF in aqueous humor of patients with neovascular glaucoma[J]. Chinese Journal of Ophthalmologic Medicine(Electronic Edition), 2018, 08(04): 163-169.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhykyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2007.2018.04.004

https://zhykyxzz.cma-cmc.com.cn/EN/Y2018/V08/I04/163

Figures/Tables 8

References 63

[1]	Hayreh SS. Neovascular glaucoma[J]. Prog Retin Eye Res，2007，26(5):470-485.
[2]	Zhou M, Chen S, Wang W, et al. Levels of erythropoietin and vascular endothelial growth factor in surgery－required advanced neovascular glaucoma eyes before and after intravitreal injection of bevacizumab[J]．Invest Ophthalmol Vis Sci，2013，54(6):3874-3879.
[3]	Zhou M, Wang J, Wang W，et al. Placenta Growth Factor in Eyes with Neovascular Glaucoma Is Decreased after Intravitreal Ranibizumab Injection[J]．PLoS One，2016，11(1):e146993.
[4]	Sims JN, Lawler J．Thrombospondin－1－Based Antiangiogenic Therapy[J]．J Ocul Pharmacol Ther，2015，31(7):366-370.
[5]	Weiss DI, Shaffer RN, Nehrenberg TR. Neovascular gluacoma complicating carotid－cavernous fistula[J]．Arch Ophthalmol，1963，69(69):304-307.
[6]	Lorenz K, Scheller Y, Bell K，et al.A prospective，randomised，placebo－controlled，double－masked，three－armed，multicentre phase II/III trial for the Study of a Topical Treatment of Ischaemic Central Retinal Vein Occlusion to Prevent Neovascular Glaucoma－the STRONG study：study protocol for a randomised controlled trial[J]．Trials，2017，18(1):128.
[7]	Moraczewski AL, Lee RK, Palmberg PF，et al.Outcomes of treatment of neovascular glaucoma with intravitreal bevacizumab[J]．Br J Ophthalmol，2009，93(5):589-593.
[8]	Degoumois A, Miocque S, Denion E．Central retinal artery occlusion without underlying chronic ocular ischemic syndrome may lead to neovascular glaucoma[J]．J Fr Ophtalmol，2017，40(9):758-762.
[9]	An TS, Kwon SI.Neovascular glaucoma due to branch retinal vein occlusion combined with branch retinal artery occlusion[J]．Korean J Ophthalmol，2013，27(1):64-67.
[10]	Kim YH, Sung MS, Park SW.Clinical Features of Ocular Ischemic Syndrome and Risk Factors for Neovascular Glaucoma[J]．Korean J Ophthalmol，2017，31(4):343-350.
[11]	Riechardt AI, Pilger D, Cordini D，et al.Neovascular glaucoma after proton beam therapy of choroidal melanoma：incidence and risk factors[J]．Graefes Arch Clin Exp Ophthalmol，2017，255(11):2263-2269.
[12]	Konareva－Kostianeva M．Neovascular glaucoma[J]．Folia Med (Plovdiv)，2005，47(2):5-11.
[13]	Vieira－Potter VJ, Karamichos D, Lee DJ.Ocular Complications of Diabetes and Therapeutic Approaches[J]．Biomed Res Int，2016，2016(3):1-14.
[14]	Yang H, Yu X, Sun X．Neovascular glaucoma：Handling in the future[J]．Taiwan J Ophthalmol，2018，8(2):60-66.
[15]	Tsai JC, Feuer WJ, Parrish RN，et al.5－Fluorouracil filtering surgery and neovascular glaucoma.Long－term follow－up of the original pilot study[J]．Ophthalmology，1995，102(6):887-893.
[16]	Mermoud A, Salmon JF, Alexander P，et al.Molteno tube implantation for neovascular glaucoma.Long－term results and factors influencing the outcome[J]．Ophthalmology，1993，100(6):897-902.
[17]	Liu L, Xu Y, Huang Z，et al.Intravitreal ranibizumab injection combined trabeculectomy versus Ahmed valve surgery in the treatment of neovascular glaucoma：assessment of efficacy and complications[J]．BMC Ophthalmol，2016，16(1):65.
[18]	Abe RY, Shigueoka LS, Vasconcellos JPC，et al.Primary Trabeculectomy Outcomes by Glaucoma Fellows in a Tertiary Hospital in Brazil[J]．J Glaucoma，2017，26(11):1019-1024.
[19]	Gedde SJ, Singh K, Schiffman JC，et al.The Tube Versus Trabeculectomy Study：interpretation of results and application to clinical practice[J]．Curr Opin Ophthalmol，2012，23(2):118-126.
[20]	Gedde SJ, Schiffman JC, Feuer WJ，et al.Three－year follow－up of the tube versus trabeculectomy study[J]．Am J Ophthalmol，2009，148(5):670-684.
[21]	Kwon HJ, Kong Y, Tao LW，et al.Surgical outcomes of trabeculectomy and glaucoma drainage implant for uveitic glaucoma and relationship with uveitis activity[J]．Clin Exp Ophthalmol，2017，45(5):472-480.
[22]	Tan AN, Cornelissen MF, Webers CAB，et al.Outcomes of severe uveitic glaucoma treated with Baerveldt implant：can blindness be prevented？[J]．Acta Ophthalmol，2018，96(1):24-30.
[23]	Sasamoto Y, Oshima Y, Miki A，et al.Clinical outcomes and changes in aqueous vascular endothelial growth factor levels after intravitreal bevacizumab for iris neovascularization and neovascular glaucoma：a retrospective two－dose comparative study[J]．J Ocul Pharmacol Ther，2012，28(1):41-48.
[24]	Zhou M, Xu X, Zhang X，et al.Clinical Outcomes of Ahmed Glaucoma Valve Implantation With or Without Intravitreal Bevacizumab Pretreatment for Neovascular Glaucoma：A Systematic Review and Meta－Analysis[J]．J Glaucoma，2016，25(7):551-557.
[25]	Wakabayashi T, Oshima Y, Sakaguchi H，et al. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases[J]．Ophthalmology，2008，115(9):1571-1581.
[26]	Ishibashi S, Kondo H．Effect of Intravitreal Bevacizumab Injection on Iris and Iridocorneal Angle Neovascularization in Neovascular Glaucoma[J]．J UOEH，2015，37(4):299-304.
[27]	Davidorf FH, Mouser JG, Derick RJ.Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection[J]．Retina，2006，26(3):354-356.
[28]	Vásquez LM, Somani S, Altomare F，et al.Intracameral bevacizumab in the treatment of neovascular glaucoma and exudative retinal detachment after brachytherapy in choroidal melanoma[J]．Can J Ophthalmol，2009，44(1):106-107.
[29]	Iliev ME, Domig D, Wolf－Schnurrbursch U，et al.Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma[J]．Am J Ophthalmol，2006，142(6):1054-1056.
[30]	Lee SJ, Lee JJ, Kim SY，et al.Intravitreal bevacizumab(Avastin)treatment of neovascular glaucoma in ocular ischemic syndrome[J]．Korean J Ophthalmol，2009，23(2):132-134.
[31]	Kahook MY, Schuman JS, Noecker RJ.Intravitreal bevacizumab in a patient with neovascular glaucoma[J]．Ophthalmic Surg Lasers Imaging，2006，37(2):144-146.
[32]	Kim ES, Yu SY, Han SB，et al.Decompression retinopathy after intravitreal bevacizumab and anterior chamber paracentesis in a patient with neovascular glaucoma[J]．Indian J Ophthalmol，2016，64(11):861-863.
[33]	Mason JR, Albert MJ, Mays A，et al.Regression of neovascular iris vessels by intravitreal injection of bevacizumab[J]．Retina，2006，26(7):839-841.
[34]	Arcieri ES, Paula JS, Jorge R，et al.Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation：2－year follow－up[J]．Acta Ophthalmol，2015，93(1):e1-6.
[35]	Silva PJ, Jorge R, Alves CR，et al.Short－term results of intravitreal bevacizumab(Avastin)on anterior segment neovascularization in neovascular glaucoma[J]．Acta Ophthalmol Scand，2006，84(4):556-557.
[36]	Sothornwit N．Intravitreal bevacizumab for ahmed glaucoma valve implantation in neovascular glaucoma：a case report[J]．J Med Assoc Thai，2008，91(Suppl 1):S162-165.
[37]	Gheith ME, Siam GA, de Barros DS，et al.Role of intravitreal bevacizumab in neovascular glaucoma[J]．J Ocul Pharmacol Ther，2007，23(5):487-491.
[38]	Marey HM, Ellakwa AF.Intravitreal bevacizumab with or without mitomycin C trabeculectomy in the treatment of neovascular glaucoma[J]．Clin Ophthalmol，2011，5(1):841-845.
[39]	Yazdani S, Hendi K, Pakravan M，et al.Intravitreal bevacizumab for neovascular glaucoma：a randomized controlled trial[J]．J Glaucoma，2009，18(8):632-637.
[40]	Cheema RA, Al－Mubarak MM, Amin YM，et al.Role of combined cataract surgery and intravitreal bevacizumab injection in preventing progression of diabetic retinopathy：prospective randomized study[J]．J Cataract Refract Surg，2009，35(1):18-25.
[41]	Chen S, Zhou M, Wang W，et al.Levels of angiogenesis－related vascular endothelial growth factor family in neovascular glaucoma eyes[J]．Acta Ophthalmol，2015，93(7):e556-e560.
[42]	Andrés－Guerrero V, Perucho－González L, García－Feijoo J，et al.Current Perspectives on the Use of Anti－VEGF Drugs as Adjuvant Therapy in Glaucoma[J]．Adv Ther，2017，34(2):378-395.
[43]	Adams JC, Tucker RP.The thrombospondin type 1 repeat (TSR) superfamily：diverse proteins with related roles in neuronal development[J]．Dev Dyn，2000，218(2):280-299.
[44]	Tucker RP.The thrombospondin type 1 repeat superfamily[J]．Int J Biochem Cell Biol，2004，36(6):969-974.
[45]	Adams JC.Thrombospondin－1[J]．Int J Biochem Cell Biol，1997，29(6):861-865.
[46]	Nunes SS, Outeiro－Bernstein MA, Juliano L，et al.Syndecan－4 contributes to endothelial tubulogenesis through interactions with two motifs inside the pro－angiogenic N－terminal domain of thrombospondin－1[J]．J Cell Physiol，2008，214(3):828-837.
[47]	Iruela－Arispe ML, Lombardo M, Krutzsch HC，et al.Inhibition of angiogenesis by thrombospondin－1 is mediated by 2 independent regions within the type 1 repeats[J]．Circulation，1999，100(13):1423-1431.
[48]	Shinkaruk S, Bayle M, Lain G，et al.Vascular endothelial cell growth factor(VEGF)，an emerging target for cancer chemotherapy[J]．Curr Med Chem Anticancer Agents，2003，3(2):95-117.
[49]	Good DJ, Polverini PJ, Rastinejad F，et al.A tumor suppressor－dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin[J]．Proc Natl Acad Sci USA，1990，87(17):6624-6628.
[50]	Suzuma K, Takagi H, Otani A，et al.Expression of thrombospondin－1 in ischemia－induced retinal neovascularization[J]．Am J Pathol，1999，154(2):343-354.
[51]	Flugel－Koch C, Ohlmann A, Fuchshofer R，et al.Thrombospondin－1 in the trabecular meshwork：localization in normal and glaucomatous eyes，and induction by TGF－beta1 and dexamethasone in vitro[J]．Exp Eye Res，2004，79(5):649-663.
[52]	Shen J, Choy DF, Yoshida T，et al.Interleukin－18 has antipermeablity and antiangiogenic activities in the eye: reciprocal suppression with VEGF[J]．J Cell Physiol，2014，229(8):974-983.
[53]	Hiscott P, Seitz B, Schlotzer－Schrehardt U，et al.Immunolocalisation of thrombospondin 1 in human，bovine and rabbit cornea[J]．Cell Tissue Res，1997，289(2):307-310.
[54]	Cursiefen C, Masli S, Ng TF，et al.Roles of thrombospondin－1 and －2 in regulating corneal and iris angiogenesis[J]．Invest Ophthalmol Vis Sci，2004，45(4):1117-1124.
[55]	Chan CK, Pham LN, Zhou J，et al.Differential expression of pro－ and antiangiogenic factors in mouse strain－dependent hypoxia－induced retinal neovascularization[J]．Lab Invest，2005，85(6):721-733.
[56]	Sheibani N, Sorenson CM, Cornelius LA，et al.Thrombospondin－1，a natural inhibitor of angiogenesis，is present in vitreous and aqueous humor and is modulated by hyperglycemia[J]．Biochem Biophys Res Commun，2000，267(1):257-261.
[57]	Hiscott P, Paraoan L, Choudhary A，et al.Thrombospondin 1, thrombospondin 2 and the eye[J]．Prog Retin Eye Res，2006，25(1):1-18.
[58]	Wang S, Gottlieb JL, Sorenson CM，et al.Modulation of thrombospondin 1 and pigment epithelium－derived factor levels in vitreous fluid of patients with diabetes[J]. Arch Ophthalmol，2009，127(4):507-513.
[59]	Elahy M, Baindur－Hudson S, Cruzat VF，et al.Mechanisms of PEDF－mediated protection against reactive oxygen species damage in diabetic retinopathy and neuropathy[J]．J Endocrinol，2014，222(3):R129-139.
[60]	Young BR, Doyle MJ, Collins WE，et al.Effect of thrombospondin and other platelet alpha－granule proteins on artificial surface－induced thrombosis[J]．Trans Am Soc Artif Intern Organs，1982，28(1):498-503.
[61]	Chowers I, Liu D, Farkas RH，et al.Gene expression variation in the adult human retina[J]．Hum Mol Genet，2003，12(22):2881-2893.
[62]	Shaw AC, Hennekam RC.Interpreting humanity's genes[J]．Eur J Med Genet，2009，52(6):379-380.
[63]	Chowers I, Gunatilaka TL, Farkas RH，et al.Identification of novel genes preferentially expressed in the retina using a custom human retina cDNA microarray[J]．Invest Ophthalmol Vis Sci，2003，44(9):3732-3741.

组别	例数	年龄(岁，±s)	性别(男/女)	眼压(mmHg，± s)	高血压[%(例数/总例数)]	糖尿病[%(例数/总例数)]
NVG组	30	65.37±14.64	16/14	44.37±6.49	33.33(10/30)	16.67(5/30)
对照组	30	67.90±5.78	17/13	14.00±2.87	0.00(0/30)	0.00(0/30)
t值/χ²值	?	－1.24^*	0.07^**	23.43^*	?	?
P值	?	>0.05	>0.05	<0.05	?	?

组别	例数	年龄(岁，±s)	性别(男/女)	眼压(mmHg，± s)	高血压[%(例数/总例数)]	糖尿病[%(例数/总例数)]
NVG组	30	65.37±14.64	16/14	44.37±6.49	33.33(10/30)	16.67(5/30)
对照组	30	67.90±5.78	17/13	14.00±2.87	0.00(0/30)	0.00(0/30)
t值/χ²值	?	－1.24^*	0.07^**	23.43^*	?	?
P值	?	>0.05	>0.05	<0.05	?	?

组别	例数	VEGF浓度(pg/ml)	TSP－1浓度(ng/ml)
NVG组	30	13.01±7.60	0.65±0.27
对照组	30	14.62±6.96	0.57±0.25
t值	?	0.86	1.16
P值	?	>0.05	>0.05

组别	例数	VEGF浓度(pg/ml)	TSP－1浓度(ng/ml)
NVG组	30	13.01±7.60	0.65±0.27
对照组	30	14.62±6.96	0.57±0.25
t值	?	0.86	1.16
P值	?	>0.05	>0.05

Please choose a citation manager

Content to export